Table 3.

Lumbar Spine and Whole Body Percentage Change in Bone Mineral Density and Change in Z Score From Baseline to Weeks 24 and 48

Location and Outcome	Time Point	Alendronate – Placebo			Treatment	No.	Mean	(95% CI)	Within-treatment P Valueb
		Mean	(95% CI)	Between-treatment P Valuea
Lumbar spine
% change BMD	24	10.00	(6.32–13.68)	< .001	Alendronate	32	14.38	(11.14–17.62)	< .001
					Placebo	18	4.38	(2.47–6.29)	< .001
	48	12.72	(6.83–18.60)	< .001	Alendronate	31	19.64	(14.10–25.18)	< .001
					Placebo	18	6.92	(4.71–9.14)	< .001
Change in Z score	24	0.60	(.36–.85)	< .001	Alendronate	32	0.76	(.57–.95)	< .001
					Placebo	18	0.16	(−.01 to .32)	.07
	48	0.73	(.41–1.05)	< .001	Alendronate	31	0.90	(.63–1.17)	< .001
					Placebo	18	0.17	(−.02 to .35)	.07
Whole body less head
% change BMD	24	3.71	(1.30–6.12)	.003	Alendronate	30	6.40	(4.41–8.39)	< .001
					Placebo	16	2.69	(1.22–4.17)	.001
	48	4.20	(.27–8.13)	.037	Alendronate	29	9.46	(6.10–12.82)	< .001
					Placebo	16	5.26	(3.02–7.51)	< .001
Whole body with head
% change BMD	24	5.11	(3.11–7.11)	< .001	Alendronate	30	6.48	(5.04–7.93)	< .001
					Placebo	16	1.38	(−.10 to 2.85)	.07
	48	6.05	(2.07–10.02)	.004	Alendronate	29	11.01	(7.73–14.29)	< .001
					Placebo	16	4.96	(2.52–7.41)	< .001
Change in Z score	24	0.54	(.36–.72)	< .001	Alendronate	30	0.50	(.38–.62)	< .001
					Placebo	16	−0.04	(−.18 to .10)	.52
	48	0.64	(.29–.98)	< .001	Alendronate	29	0.82	(.53 −1.10)	< .001
					Placebo	16	0.18	(−.03 to .39)	.09

Abbreviations: BMD, bone mineral density; CI, confidence interval.

^a t test with unequal variances for treatment differences.

^b t test for within-group change.